MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data
Executive Overview In a significant development for the global oncology landscape, pharmaceutical giants MSD (known as Merck & Co. in...
Executive Overview In a significant development for the global oncology landscape, pharmaceutical giants MSD (known as Merck & Co. in...